コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 If the patient is experiencing pain or suffering, treatment t
2 If the patients' exposure times are long enough to evaluate s
3 The Kaplan-Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomiza
4 ntile and a glycated hemoglobin level between 7.0 and 11.0% if the patients were being treated with diet and exercise alo
5 coming RN did not know the patient (F(1,155)=6.51, p=<.05), if the patient was expected to die during the shift (F(1,155)
6 a surgical procedure (n = 42,143) or medical (n = 149,137) if the patient did not receive surgical treatment in the last
7 r-free days at day 28 (score ranged from -1 for death to 27 if the patient was off ventilator on the first day).
8 tality before hospital discharge home or until study day 60 if the patient was still in a health care facility.
9 d 1 (PD-L1) expression, pembrolizumab should be used alone; if the patient has low PD-L1 expression, clinicians should of
11 stinence period, and quantification of alcohol intake), and if the patient is an active drinker, liver elastography can b
12 icipant, we determined how mean deviation (MD) would change if the patient maintains his/her IOP at 1 of 7 levels (6, 9,
13 Substitutions must be followed by control visits to check if the patient is taking the medication correctly and if drug
15 formed at baseline, after two cycles (and after four cycles if the patient was PET-positive after two cycles), and at the
16 Operability assessment is then undertaken to determine if the patient is a candidate for potentially curative pulmon
17 CI and related to the initial admission, or until discharge if the patient was readmitted within 90 days of surgery, were
18 atient, our data support selecting a CMV-seropositive donor if the patient receives a myeloablative conditioning regimen.
19 the possibility to distinguish between CAP and AECOPD even if the patient with CAP had COPD, with a panel of CD45, CD28,
20 CE 6: Clinicians should pursue evaluation of hematuria even if the patient is receiving antiplatelet or anticoagulant the
21 patients with coronary artery disease requiring DAPT, even if the patients are on low-dose aspirin.
22 ations, and as we see through history, this may only happen if the patient believes there is an actual neuromodulatory ef
23 8-fold higher if patients were aged <5 years, 5-fold higher if the patient had any evidence of bleeding, and 5.2-fold hig
24 women aged between 30 and 60 years and this risk was higher if the patient had chronic hypertension.
27 ised controlled trials of inhaled antibiotics were included if the patients were adults with stable bronchiectasis diagno
29 patients with COPD receiving triple therapy (ICS/LABA/LAMA) if the patient has had no exacerbations in the past year; 4)
31 e FOM, the concordance across all treatment plans was lower if the patients had ADT claims within 180 d before NaF PET.
32 g dose was 60 mg/day orally but could be escalated to 80 mg if the patient did not experience a response.
34 o patients with ascites/HE and measuring HVPG response only if the patient's baseline HVPG is over 16 mm Hg improves dete
35 cerebellar ataxia (odds ratio, 10.5; 95% CI, 3.2-34.5), or if the patient had coexisting neuronal cell-surface antibodie
36 ad a secondary ICD-9-CM diagnosis code for Crohn disease or if the patient was not continuously enrolled in an insurance
37 remains for patients at borderline or intermediate risk, or if the patient is undecided after a patient-clinician discuss
38 remains for patients at borderline or intermediate risk, or if the patient is undecided after a patient-clinician discuss
39 (if not previously administered) and may offer pertuzumab, if the patient has not previously received it.
41 approach beginning with more simple care that is progressed if the patient does not respond, and the use of simple risk p
42 l carcinoma (without positive markers, eg, EGFR/ALK /ROS1), if the patient has high programmed death ligand 1 (PD-L1) exp
43 use medical therapies over a defined period of time to see if the patient improves or deteriorates according to agreed-u
44 t TKI-resistant low-level mutations are invariably selected if the patients are not switched to another TKI or if they ar
45 Treatment outcomes were defined as successful if the patient was cured or completed treatment and unsuccess
46 Outcomes were considered successful if the patients had deviations less than 10 prism diopters (P
47 information found lower failure to receive glucose testing if the patient received care at a CMHC (0.74 [0.64-0.85]) or
48 e patient was cured or completed treatment and unsuccessful if the patient died or defaulted from treatment or if treatme
49 CI, 5.0-15.8) and varied based on the following variables: if the patient was on complex care service (5.3 minutes [95%
50 ability of remaining disease-free for an additional 3 years if the patient survived without disease at 1, 3, and 5 years,